Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70336 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Francoise Bernaudin und 40 weiteren Autor:innen. Beteiligte Einrichtung: Referral Center for Sickle Cell Disease, CHIC Hospital, Créteil, France. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Hematopoietic Stem Cell Transplantation, Cerebrovascular Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence de la Biomédecine, Pfizer France.
Abstract (Originalsprache)
Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in 67 (35F/32M) SCA children (5–15 year) on CT for abnormal time‐averaged mean maximum velocities (TAMMV ≥ 200 cm/s). Seven had a stroke history. We reported that MSD‐HCT reduced the highest TAMMVs at 1‐ and 3‐year ( p < 0.001) and improved quality of life (QoL) for physical and school functioning. In stroke‐free patients, the 3‐year stenosis score was lower ( p = 0.010). Nevertheless, no significant difference was observed for silent cerebral infarcts (SCI) and cognitive performance. This prompted us to initiate DREPAGREFFE‐2 to reevaluate the outcomes at 10 years (September 2022/August 2024) with the same 67 SCA children. No death or stroke occurred in either arm. No rejection or chronic‐GvHD arose in the MSD‐HCT group ( n = 32). In the standard‐care group ( n = 35), 16 were on hydroxyurea, and 16 on CT at Year 10, and 3 received haploidentical‐HCT. After MSD‐HCT, the QoL was better, even for social functioning, and the number of hospitalizations, hospitalized days ( p < 0.001), and crises ( p = 0.001) was lower than on standard‐care. In stroke‐free patients, stenosis ( p = 0.027) and SCI scores ( p = 0.041) decreased significantly more after MSD‐HCT than on standard‐care; working memory ( p = 0.016) and processing speed ( p = 0.011) improved significantly after MSD‐HCT, but worsened on standard‐care. These effects were not previously detected with shorter follow‐up. This supports earlier consideration of HCT for SCA children with MSD to preserve neurologic function and QoL for a more productive future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Referral Center for Sickle Cell Disease, CHIC Hospital, Créteil, France.
- Clinical Research Department, CHIC Hospital, UPEC University, Créteil, France.
- Medical Imaging, Referral Center For Sickle Cell Disease, CHIC Hospital, Créteil, France.
- Pediatric Imaging, Robert Debré Paris Hospital, Referral Center for Sickle Cell Disease, Paris, France.
- Neuropsychiatry Department, CHIC Hospital, Créteil, France.
- Referral Center for Sickle Cell Disease, CHU Pointe à Pitre, Pointe à Pitre, Guadeloupe, France.
ORCID-Profile: Francoise Bernaudin, Corinne Pondarré, Giovanna Cannas, Mariane de Montalembert, Catherine Poirot, Pierre Frange, Bénédicte Bruno, Camille Jung
Förderung
- Agence de la Biomédecine
- Pfizer France
Zitieren
APA
Bernaudin, F., Verlhac, S., Ducros-Miralles, E., Arnaud, C., Genty, I., Petras, M., Paillard, C., De Luna, G., Meunier, B., Thuret, I., Kamdem, A., Pondarré, C., Cannas, G., Chantalat-Auger, C., Firah, N., Pertuisel, S., Joseph, L., Missud, F., de Montalembert, M., …, & Jung, C. (2026). Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial. American Journal of Hematology. https://doi.org/10.1002/ajh.70336
Vancouver
Bernaudin F, Verlhac S, Ducros-Miralles E, Arnaud C, Genty I, Petras M, et al. Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial. American Journal of Hematology. 2026. doi:10.1002/ajh.70336
BibTeX
@article{Bernaudin2026,
author = {Bernaudin, Francoise and Verlhac, Suzanne and Ducros-Miralles, Elisabeth and Arnaud, Cécile and Genty, Isabelle and Petras, Marie and Paillard, Catherine and De Luna, Gonzalo and Meunier, Benoit and Thuret, Isabelle and Kamdem, Annie and Pondarré, Corinne and Cannas, Giovanna and Chantalat-Auger, Christelle and Firah, Nadia and Pertuisel, Sophie and Joseph, Laure and Missud, Florence and de Montalembert, Mariane and Guitton, Corinne and Pluchart, Claire and Brousse, Valentine and Elmaleh, Monique and Gajdos, Vincent and Leveillé, Emmanuella and Belozertseva, Ekaterina and Gaba, Mabel and Poirot, Catherine and Barraud-Lange, Virginie and Chadebech, Philippe and Pirenne, France and Bernaudin, Myriam and Neven, Bénédicte and Frange, Pierre and Angoso, Marie and Yakouben, Karima and Bruno, Bénédicte and Dhédin, Nathalie and Dalle, Jean-Hugues and Delatour, Regis Peffault and Jung, Camille},
title = {Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70336}
}
EUVIMED